Stocktoria
Cue Biopharma, Inc. CUE
Cue Biopharma, Inc. (CUE) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $27.5M at a -96.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
| VSTM | Verastem, Inc. | 4/9 | -15.71 | — | +209.1% |
| ZOMDF | Zomedica Corp. | 3/9 | 1.07 | — | +17.4% |
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
FAQ
Is CUE financially healthy?
Cue Biopharma, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does CUE pay a dividend?
No, Cue Biopharma, Inc. does not currently pay a dividend.
How profitable is CUE?
In FY2025, Cue Biopharma, Inc. had a net margin of -96.9% and a return on equity of -100.6%.
What is the analyst price target for CUE?
The average Wall-Street price target for Cue Biopharma, Inc. is $115.00, about 278.0% above the recent price, from 1 analysts.
Is CUE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cue Biopharma, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.